Onetouch ultra blood glucose

Pre-anesthetic tail vein blood samples were obtained for measurements of fasting blood glucose (OneTouch® Ultra Blood Glucose, Lifescan Inc., CA, USA).

Before the experiments a tail blood was sampled after 12 h fasting to validate development of T2DM by analyzing circulating blood glucose (OneTouch^® Ultra Blood Glucose, lifescan Inc., CA, USA) and insulin levels (AlphaLISA^® Insulin Kit, PerkinElmer, MA, USA). The rats were randomly allocated to 10 experimental groups (n = 8): (I–IV) Perfusion with 11 mmol/L Glucose (normoglycemia) (I: DM Control, II: DM IPC, III: Non-DM Control, IV: Non-DM IPC), and (V–X) perfusion with 22 mmol/L Glucose (hyperglycemia) (V: DM Control, VI: DM IPC, VII: DM intensified IPC, VIII: Non-DM Control, IX: Non-DM IPC, X: Non-DM intensified-IPC). Hyperglycemia at a glucose concentration of 22 mmol/L was used as this concentration has previously been used in studies of hyperglycemia [23 (link)]. After 20 min of stabilization IPC hearts were preconditioned by 2 × 5 min of global ischemia, a stimulus that is stronger than we have previously used [5 (link)], because it has been demonstrated that an enhanced stimulus is needed to elicit cardioprotection in diabetic rats [7 (link)]. Each period of global ischemia was followed by 5 min of reperfusion. The intensified IPC protocol consisted of 4 × 5 min ischemia and reperfusion. Subsequently all hearts were subjected to 40 min of global ischemia and 2 h of reperfusion.

To validate the disease model preanesthetic tail vein blood was drawn for measurement of glucose (One Touch® Ultra Blood Glucose, Lifescan Inc., CA, USA) and insulin levels (DRG Instruments, Marburg, Germany) at the beginning of each test day and no later than an hour prior to surgery. Plasma total cholesterol and triglycerides were measured in blood samples drawn from the abdominal aorta during surgery. Preparation for insulin and lipid profile measurements where done as previously described[19 (link)].